Go to Cognosci home page
Company spacer Technology spacer Pipeline spacer Partnering spacer News


   bullet  About Us

   bullet  Management

   bullet  Advisors

   bullet  Contact Us


   bullet  APOE and Human
   bullet  Disease

   bullet  APOE and
   bullet  Inflammation

   bullet  Cognosci APOE
   bullet  Compounds

   bullet  Publications


   bullet  Multiple Sclerosis

   bullet  Alzheimer’s Disease

   bullet  Traumatic Brain
   bullet  Injury


   bullet  Multiple Sclerosis

   bullet  Alzheimer’s Disease

   bullet  Subarachnoid
   bullet  Hemorrhage


   bullet  Latest News


Millions of patients suffer from the disability from diseases including:

  • Multiple sclerosis

  • Stroke/Subarachnoid hemorrhage

  • Traumatic brain injury

  • Spinal cord injury

  • Alzheimer's disease

  • Parkinson's disease

  • Rheumatoid arthritis

In each of these disorders, inflammation plays a critical role in the development and progression of the disease. In neurodegenerative diseases, inflammation in the brain damages neurons and leads to nerve cell death that is marked by declining cognitive and motor function and eventually contributes to the death of the patient.

COG-133 Cognosci is discovering and developing therapeutic compounds to restore healthy function in these life-threatening diseases. These compounds are small patented synthetic peptides of ten to seventeen amino acids that are based on the multifunctional apoE protein, and have potent in vitro and in vivo anti-inflammatory activity.

In addition to inhibiting inflammation, Cognosci's compounds also directly protect nerve cells by blocking activity of endogenous neurotoxins released by injured brain cells. This novel dual action, immune suppression and direct neuroprotection, is unique among compounds being developed as therapeutics for neurodegenerative disorders. Cognosci's are novel therapeutics that are changing the paradigms for treatment of these neurological and inflammatory diseases with unique anti-inflammatory, neuroprotective and neuro-reparative properties.

The Company has developed a deep pipeline of programs in various stages of development with some programs in preclinical development and other programs in lead optimization. Our goal is to identify compounds that are efficacious in predictive animal models and to pursue clinical development of drugs for Multiple Sclerosis, Traumatic Brain Injury, Stroke, Subarachnoid Hemorrhage, Spinal Cord Injury, and Rheumatoid Arthritis through proof of concept in Phase II human clinical trials.

spacer Latest News

Cognosci Receives Funding for Advanced Testing of Lead Drug Candidate for the Treatment of Multiple Sclerosis

For more information, contact:

Cognosci Inc.
79 T. W. Alexander Drive
4401 Research Commons
Research Triangle Park
NC 27709
(919) 765-0028